Monitor upcoming clinical data readouts for sutacimig in late 2026/early 2027, as success could validate the company's approach but failure would significantly impact the stock. Watch for updates on the remediation of material weaknesses in internal controls, as unresolved issues could delay financial reporting.
Executive Summary
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotech company developing therapies for rare blood coagulation disorders. Its lead asset, sutacimig, showed a 47% reduction in bleeding events in a Phase 1/2 trial for Glanzmann thrombasthenia, with data from a Phase 2 trial for Factor VII deficiency expected in late 2026. The company plans to use $180.3 million in IPO proceeds to fund clinical development, but faces significant risks including a history of increasing losses, serious adverse events of thrombosis in trials, and a material weakness in its internal controls.
Key Financial Metrics
Key Facts
- Company is developing therapies for rare blood coagulation disorders like Glanzmann thrombasthenia and Factor VII deficiency.
- Lead asset sutacimig showed a 47% reduction in mean annualized treated bleed rate in a Phase 1/2 trial for Glanzmann thrombasthenia.
- Company raised $180.3 million in net proceeds from its IPO to fund clinical development of its product candidates.
- Serious adverse events of thrombosis were identified in the development of sutacimig, including one grade 2 proximal deep vein thrombotic event.
- Company has identified material weaknesses in its internal control over financial reporting.
- Net losses increased from $48.7 million in 2024 to $63.9 million in 2025.
Financial Impact
The company raised $180.3 million in net proceeds from its IPO to fund clinical development, but has not generated any revenue and reported net losses of $63.9 million in 2025.
Risk Factors
- Clinical development risks including serious adverse events of thrombosis observed in trials
- Financial risks due to increasing net losses and dependence on future funding
- Operational risks from material weaknesses in internal control over financial reporting
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-178809 |
| Document: d50309dex11.htm | 0001193125-26-178809 |
| Document: d50309dex107.htm | 0001193125-26-178809 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | โผ โ10.77% | โผ โ9.71% | $30.36 (โ39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | โฒ +52.29% | โฒ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | โฒ +21.03% | โฒ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | โฒ +9.88% | โฒ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | โผ โ20.21% | โผ โ25.47% | $30.36 (โ10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | โผ โ20.21% | โผ โ25.47% | $30.36 (โ10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | โผ โ20.21% | โผ โ25.47% | $30.36 (โ10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | โผ โ20.21% | โผ โ25.47% | $30.36 (โ10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | โผ โ20.21% | โผ โ25.47% | $30.36 (โ10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | โผ โ20.21% | โผ โ25.47% | $30.36 (โ10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access